Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Opko Health, a specialty healthcare company, has started treating patients in a clinical trial of its Aquashunt, a device for the treatment of refractory open angle glaucoma.
Subscribe to our email newsletter
The study, at two academic departments of ophthalmology, is designed to assess the safety and efficacy of the Aquashunt and will enroll up to 20 patients with significantly impaired visual acuity.
The Aquashunt is a novel device designed to lower intraocular pressure by allowing excess fluid in the eye to exit more naturally than occurs with presently available devices.
Bruce Shields, professor of ophthalmology at Yale University and designer of the Aquashunt, said: “We are pleased by the simplicity of the surgical procedure for the device and by the early results in the first human trials. These early results provide further validation of our optimism for the future of the Aquashunt, and we look forward to completing our clinical trials and bringing this product to market.”